BH3:ETR
PTC Therapeutics, Inc.
€57.42
arrow_upward
+0.88%(+0.50) 1D
Sep 30, 5:35:31 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BH3...
Open
€57.18
High
€57.42
Low
€57.18
Mkt. cap
5.41B
Avg. vol.
5.00
Volume
0.00
52-wk high
€78.18
52-wk low
€54.42
No. of employees
991
Open
€57.18
High
€57.42
Low
€57.18
Mkt. cap
5.41B
Avg. vol.
5.00
Volume
0.00
52-wk high
€78.18
52-wk low
€54.42
No. of employees
991
News stories
From web sources and news partners
Stock Titan
·
12 hours ago
A director proposes selling $782K in option-exercised PTC Therapeutics (PTCT) shares.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com